To further understand the role of FAK in the development of liver fibrosis in vivo, mice were treated with intraperitoneal carbon tetrachloride (CCl4) injections, followed by daily treatment of FAK inhibitor (PF562271) (Fig. 6). This evidence concerns the gene PTK2 and Hepatic fibrosis.